Abstract. Epigenetic alterations of the histone acetylation play an important role in the regulation of gene expression associated with cell cycles and apoptosis that may affect the chemosensitivity of gastric carcinomas. Recently, a histone deacetylase inhibitor, trichostatin A (TSA), was proven to be a chemo-sensitizer on human erythroleukemia cells. With the aim of improving the chemotherapeutic efficacy of gastric carcinoma, the effect of TSA on the chemosensitivity of several anticancer drugs in gastric carcinoma cells was investigated. Human gastric cancer cell lines, OCUM-8 and MKN-74, and 5 anticancer drugs, 5-fluorouracil (5-FU), paclitaxel (PTX), oxaliplatin (OXA), irinotecan (SN38) and gemcitabine (GEM) were used. In both gastric cancer cell lines, a synergistic anti-proliferative effect by the combination of TSA (30 ng/ml) with 5-FU, PTX or SN38 showed a synergistic anti-proliferative effect in OCUM-8 and MKN-74 cells. TSA increases the expression of p21, p53, DAPK-1 and the DAPK-2 gene in both OCUM-8 and MKN-74 cells. In conclusion, TSA is a promising chemotherapeutical agent in combination with anticancer drugs of 5-FU, PTX and SN38 in gastric cancer cell lines. The up-regulation of p53, p21, DAPK-1 and DAPK-2 might be associated with the synergistic effect of TSA.
Introduction
Gastric carcinoma remains one of the major causes of cancer deaths around the world (1, 2) . Most patients with advanced gastric cancer need chemotherapy. Among the chemotherapeutical agents for gastric cancer, 5-fluorouracil (5-FU) remains the primary agent used, while recently several new drugs, including the taxanes such as paclitaxel (PTX), the thirdgeneration platinum derivative oxaliplatin (OXA), the topoisomerase-I inhibitor irinotecan (SN38), and the pyrimidine analog gemcitabine (GEM) have emerged. These agents provide a better prognosis for patients with advanced gastric cancer (3) (4) (5) (6) . Even so, the response rate is low (20-40%) . Combination chemotherapy using anticancer drugs achieves a better response rate, exceeding the efficacy of single treatment, but carries a high-risk of side effects. With the aim of improving the chemotherapeutic efficacy of gastric carcinoma, a novel combination regimen of anticancer drugs with a synergistic effect was investigated in this study.
The chemosensitivity of gastric carcinomas is influenced by changes in genes, including those known to be associated with cell cycles and apoptosis (7) . There is increasing evidence that epigenetic alterations, such as the histone acetylation and the promoter methylation, play an important role in the regulation of gene expression associated with cell cycles and apoptosis (8) . Histone acetylation relaxes the normally tight supercoiling of chromatin, enhancing the accessibility of DNA-binding transcriptional regulatory proteins to promoter regions, which is often associated with transcriptional activation of genes that regulate cell cycle progression, DNA replication and the apoptotic response to DNA damage. In contrast, histone deacetylation, catalyzed by histone deacetylase (HDAC), is often associated with transcriptional silencing through chromatin condensation. Aberrant levels of HDAC activity have been found in a variety of human malignancies and result in the repression of tumor-suppressor genes and the promotion of tumorigenesis (9) . HDAC inhibitors represent a structurally diverse group of compounds that inhibit the deacetylation of histones, permitting the chromatin scaffolding to assume a more relaxed, open conformation, which generally promotes gene transcription. Because HDAC inhibitors induce apoptosis in neoplastic cells through multiple mechanisms, HDAC inhibitors are emerging as a promising new therapeutic tool for treatment of a variety of human tumors (10) . HDAC inhibitors represent different mechanisms from conventional anticancer drugs. Inappropriate transcriptional repression mediated by HDACs is an important reason for the loss or down expression of tumor suppressor genes (11, 12) . HDAC inhibitors induce differentiation (13) , inhibit tumor growth (14) , trigger apoptosis (15, 16) , and regulate the cell cycle (17) . HDAC inhibitors have recently been applied to some clinical trials such as a phase I study of suberoylanilide hydroxamic acids in patients with advanced solid tumors or hematological malignancies (18) , and a phase II study of FR901228 in patients with cutaneous T-cell lymphoma or relapsed peripheral T-cell lymphoma (19) .
The HDAC inhibitor trichostatinA (TSA) is one of the histone deacetylases that regulates gene expression epigenetically (9, 20) . Since the inhibition of the cell growth by TSA at low nM concentrations has not been reported in nonneoplastic cells, TSA may be a prospective candidate chemotherapeutic agent to use in combination with other agents to form more effective regimens (20) . TSA has been proven to be a radio-or chemo-sensitizer on human erythroleukemia cells (21) . However, no studies have been conducted to elucidate the effect of TSA on the chemosensitivity of several anticancer drugs in gastric carcinoma cells. Here, we report that the HDAC inhibitor interacts with anticancer drugs in a highly synergistic manner in gastric cancer cell lines to induce the activation of apoptosis.
Materials and methods

Chemicals and anticancer drugs.
A stock solution of TSA (Wako, Osaka, Japan) at 10 mg/ml was prepared in dimethyl sulfoxide (DMSO; Wako). Five anticancer drugs, 5-FU (Kyowa Hakko, Tokyo, Japan), PTX (Bristol-Myers, Wallingford, CT), Oxaliplatin (OXA; Yakult, Tokyo, Japan), irinotecan active metabolite SN38 (Yakult, Tokyo, Japan) and gemcitabine (GEM, Eli Lilly, Kobe, Japan), were used in this study. All reagents were formulated as recommended by their suppliers.
Cell culture and cell lines. The human gastric cancer cell lines OCUM-8 (22) and MKN-74 (23) were used in this study. OCUM-8 was cultured in Dulbecco's modified Eagle's medium (DMEM; Nikken Biomedical Laboratory, Kyoto, Japan), while MKN-74 was cultured in RPMI-1640 medium (Sigma, Tokyo, Japan). Both media were supplemented with 10% fetal bovine serum, 100 IU/ml penicillin (ICN Biomedical, Costa Mesa, CA), 100 μg/ml streptomycin (ICN Biomedical), and 0.5 mM sodium pyruvate (Cambrex, Walkersville, MD). The cells were cultured at 37˚C in a humidified atmosphere of 5% CO 2 in air.
Cell growth assays. Cancer cells (5x10 4 ) were placed in each well of a 96-well plate. With or without the addition of TSA (30 ng/ml), and with or without anticancer drugs at the IC 50 , the plates were incubated for 72 h at 37˚C. The suppression of cell proliferation was examined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, St. Louis, MO) colorimetric assay in which the formazan product of MTT was measured as absorbance at 550 nm using a microtiter plate reader (Model 550; Bio-Rad Laboratories, Tokyo, Japan). The percentage of cell viability was determined as the ratio absorbance of the sample versus the control. The IC 50 of each drug was determined as a drug concentration showing 50% cell growth inhibition as compared with the control cell growth. Six replicate wells were used for each drug concentration, and the testing was carried out independently for 3 times. The potential synergy between the drugs and TSA was evaluated as follows, using Drewinko's fraction method (24) . The synergistic, semi-additive and antagonistic Table I . Primer sequences. 
interactions were determined when the value was less than the expected value, more than the expected value but less than the drugs' value, and more than the drugs' value, respectively. The expected value of the combined effects (%) = the effects of the anticancer drug/control x the effects of the TSA/control x 100 was calculated.
Reverse transcription PCR. We examined the expression at the mRNA level of genes, including apoptosis related genes, caspase-3, bcl-2 and death associated protein kinase family members 1, 2, and 3 (DAPK-1, DAPK-2 and DAPK-3), tumor suppressor gene p53 and Rb, and cell cycle regular p21 WAF1/Cip1 . The cells were seeded in a 100-mm dish with the final concentration of 2.5x10 4 cells/ml, with or without TSA at 30 ng/ml. After incubation of 48 h, total cellular RNA was extracted from OCUM-8 and MKN-74 using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. After the genomic DNA was removed by DNAse, cDNA was prepared from 1 μg of RNA with Maloney mouse leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA) using random primers (Invitrogen). The relevant cDNA were amplified by PCR using the primer pairs (Table I) with TaqDNA polymerase (Invitrogen) in a thermal cycler. The PCR conditions were as follows: predenaturation at 94˚C for 3 min, denaturation at 94˚C for 30 sec, annealing at 59˚C for 30 sec, extension at 72˚C for 1 min with 35 cycles of the three repeated steps, and final incubation at 72˚C for 10 min. The PCR products were applied to 2% agarose gel and electrophoresed. The mRNA level of the each gene was normalized by the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Statistical methods. The quantitative ratios of different groups were compared using the Student's t-test. Probability values of P<0.05 were regarded as statistically significant. All statistical tests were two-sided. The synergistic, semi-additive and antagonistic interactions were determined when the value was less than the expected value, more than the expected value but less than the drugs' value, and more than the drugs' value, respectively. The expected value of the combined effects (%) = effects of anticancer drug/control x effects of TSA/ control x 100 was calculated. The results are presented as the mean of three independent experiences, and the bars indicate the SD. * p<0.05; ** p<0.01; compared with each anticancer drug alone. Exp, an expected additive value; NS, not significant. the proliferation of cancer cells in both cell lines. The proliferation rate by TSA was 84.8 and 94.4% in the OCUM-8 and MKN-74 cells, respectively. Anticancer drugs were added to the cancer cell cultures at a concentration causing 50% growth inhibition (IC 50 ) for each cell line. Table II (Fig. 2) .
Results
HDAC inhibitor increased the efficiency of anticancer drugs.
Discussion
In this study, TSA increased the chemosensitivity of anticancer drugs in human gastric cancer cells. A synergistic antiproliferative effect by the combination of TSA was observed in 5-FU, PTX or SN38. 5-FU is a pyrimidine antagonist that inhibits DNA synthesis and blocks the production of RNA. PTX is a kind of taxane-based drug that interferes with mitosis and cell replication by binding to a subunit of tubulins. SN38 is a DNA topoisomerase I inhibitor that interferes with DNA replication and cell division. These 3 anticancer drugs have different mechanisms, and are frequently used clinically. PTX and SN38 are generally used weekly or biweekly. The adminis-tration of TSA for 48 h enhanced these genetic changes. Taken together, because no antagonistic interactions were found in the combination of TSA with the 5 anti-cancer drugs examined in this study, TSA has wide chemotherapeutic efficacy with various types of anticancer drugs in gastric carcinoma. It has been reported that 500 ng/ml TSA significantly inhibited the growth of gastric cancer cells (25) . In this study, a low dose of TSA (30 ng/ml) showed a synergistic effect with anticancer drugs. Since TSA is reported to be toxic (26) , a low dose of TSA is appropriate for clinical use. Because these genetic alterations of mRNA by the HDAC inhibitor are reversible, two days of administration of TSA with PTX or SN38 in a week might be safe. To our knowledge, this is the first report stating that TSA shows a synergistic effect in combination with anticancer drugs in gastric cancer.
HDAC inhibitors are capable of inducing apoptosis and cell cycle arrest at the G1 or G2 phase by the alteration of gene expressions (15) (16) (17) 21, (27) (28) (29) (30) . In our study, DAPK-1 and DAPK-2 were up-regulated by TSA in gastric cancer cells, but not DAPK-3. DAPK-1 and DAPK-2 are responsible for the induction of apoptosis, while DAPK-3 usually induces morphological changes in apoptosis (31) . The loss of DAPK expression has been documented in many cancer types (24, 30, 32, 33) . These findings suggest that DAPK-1 and DAPK-2 might participate in the synergism by the co-treatment of TSA and anticancer drugs.
It has been well proven that HDAC inhibitors could upregulate the transcription of both p53 and p21 (17, (34) (35) (36) , and that they could also induce the hypophosphorylated form of 
IC 50 was determined as a concentration causing 50% growth inhibition for each cell line. The values indicated correspond to the result of three independent studies expressing in mean ± SD.
- Rb (21) , which usually leads to a cell cycle arrest at the G1 phase. Consistent with the previous study, our study also shows that TSA enhanced the expression of p53 as well as p21, while the mRNA level of Rb was not changed by TSA. The cell cycle is regulated by a complicated network that involves a number of regulators, such as p21 WAF1/CIP1 , p53 and Rb. P21 was initially discovered as a negative regulator of cell cycle progression. Since OCUM-8 and MKN-74 cells possess the wild p53 gene, the p21 might be up-regulated by TSA and/or p53.
The expression level of caspase-3 mRNA increased in OCUM-8 but not MKN-74, suggesting that caspase-3 might take part in chemosensitivity increased by TSA. Although no study supports that the transcription of caspase-3 can be upregulated directly by histone acetylation, recent evidence suggests that HDAC inhibitors also enhance the acetylation of non-histone proteins (37, 38) . No alteration of bcl-2 was presented after 48 h exposure to TSA, indicating that the bcl-2 family might not contribute to the enhanced chemosensitivity of TSA.
In conclusion, TSA increased the chemosensitivity of anticancer drugs of 5-FU, PTX and SN38 in gastric cancer cells. The up-regulation of p53, p21, DAPK-1 and DAPK-2 might explain the mechanism of synergism.
